Comparative Pharmacology
Head-to-head clinical analysis: LORAZEPAM PRESERVATIVE FREE versus XANAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORAZEPAM PRESERVATIVE FREE versus XANAX.
LORAZEPAM PRESERVATIVE FREE vs XANAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and producing sedative, anxiolytic, anticonvulsant, and muscle relaxant effects.
Alprazolam is a benzodiazepine that binds to the gamma-aminobutyric acid (GABA)-A receptor at the α1, α2, α3, and α5 subunits, enhancing the effect of GABA by increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of neurotransmission.
0.5-2 mg orally every 6-8 hours as needed; maximum 4 mg/day. IV: 0.044 mg/kg (max 4 mg) every 6-8 hours for acute anxiety or sedation.
Initial: 0.25-0.5 mg orally 3 times daily; maximum: 4 mg/day in divided doses. For panic disorder: 0.5-1 mg at bedtime or 0.5 mg 3 times daily; titrate as needed up to 10 mg/day.
None Documented
None Documented
Terminal elimination half-life: 12–14 hours (range 10–20 h). Clinically, no active metabolites; accumulation minimal at standard dosing intervals.
Terminal elimination half-life: 11.2 hours (range 6.3–26.9 hours). With repeated dosing, half-life may prolong slightly; clinical context: allows once-daily dosing for most patients.
Renal: ~88% as glucuronide conjugates; <1% unchanged. Fecal: ~7%. Biliary: minor.
Renal: ~80% (mainly as glucuronide metabolites, <20% unchanged). Fecal: <7%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine